Literature DB >> 29703903

IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity.

Ayako Takamori1,2, Aya Nambu1, Keiko Sato1, Sachiko Yamaguchi1, Kenshiro Matsuda3, Takafumi Numata1,4, Takeru Sugawara1, Takamichi Yoshizaki1,5, Ken Arae6, Hideaki Morita6, Kenji Matsumoto6, Katsuko Sudo7, Ko Okumura2, Jiro Kitaura2, Hiroshi Matsuda3, Susumu Nakae8,9.   

Abstract

IL-31, which is a member of the IL-6 family of cytokines, is produced mainly by activated CD4+ T cells, in particular activated Th2 cells, suggesting a contribution to development of type-2 immune responses. IL-31 was reported to be increased in specimens from patients with atopic dermatitis, and IL-31-transgenic mice develop atopic dermatitis-like skin inflammation, which is involved in the pathogenesis of atopic dermatitis. However, the role of IL-31 in development of contact dermatitis/contact hypersensitivity (CHS), which is mediated by hapten-specific T cells, including Th2 cells, is not fully understood. Therefore, we investigated this using IL-31-deficient (Il31-/-) mice, which we newly generated. We demonstrated that the mice showed normal migration and maturation of skin dendritic cells and induction of hapten-specific T cells in the sensitization phase of FITC-induced CHS, and normal induction of local inflammation in the elicitation phase of FITC- and DNFB-induced CHS. On the other hand, those mice showed reduced scratching frequency and duration during FITC- and/or DNFB-induced CHS. Our findings suggest that IL-31 is responsible for pruritus, but not induction of local skin inflammation, during CHS induced by FITC and DNFB.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29703903      PMCID: PMC5923199          DOI: 10.1038/s41598-018-25094-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

IL-31, which is a member of the IL-6 family of cytokines, is produced mainly by activated CD4+ T cells, in particular activated Th2 cells, mast cells, macrophages and dendritic cells[1-4].Human and mouse IL-31 genes are located on chromosome 12q24.31 and chromosome 5, respectively, and their amino acid sequences show 31% homology[1]. Expression of IL-31 mRNA was reported in various human tissues, such as the testis, bone-marrow, skeletal muscle and kidney[1]. The receptor for IL-31 is a heterodimer, consisting of IL-31 receptor A (IL-31 RA) and oncostatin M receptor (OSMR)[1]. In humans and/or mice, IL-31 RA mRNA expression is found in various tissues, such as the testis, bone marrow, skin and dorsal root ganglia, and in various cells, such as activated monocytes, macrophages, dendritic cells (DCs), eosinophils, basophils and keratinocytes, while OSMR mRNA is broadly expressed in many tissues[5-7]. In cultures of various human cell lines such as keratinocytes[1], intestinal and bronchial epithelial cell lines[8,9], DCs[7], monocytes and macrophages[10], IL-31 has been shown to induce expression of such cytokines as IL-6, IL-8 and/or TNF and such chemokines as CCL2, CCL4, CCL5, CCL17 and/or CCL22. IL-31 has been implicated to be involved in the pathogenesis of such allergic disorders as rhinitis, asthma and dermatitis[5]. Indeed, increased levels of IL-31 were observed in nasal secretions of patients with allergic rhinitis[11]. IL-31 levels in sera or PBMCs were significantly increased in patients with asthma[12], and IL-31 can activate human bronchial epithelial cell lines, as described above. However, ovalbumin-induced airway inflammation developed normally in mice treated with anti-IL-31RA neutralizing Ab[13], suggesting that IL-31 is not crucial for induction of allergic airway inflammation in that model. In regard to skin diseases, elevated levels of IL-31 were observed in such specimens as plasma, sera and/or cutaneous biopsies from patients with atopic dermatitis[14,15] or contact dermatitis[16]. In particular, IL-31 was implicated in itching by inducing activation of sensory nerve cells[5]. In support of that notion, transgenic mice (Tg mice), which express IL-31 systemically or specific for lymphocytes, spontaneously develop skin inflammation resembling human atopic dermatitis and show severe scratching behavior accompanied by exfoliation of epidermis[1]. Expression of IL-31 mRNA was increased in inflamed lesions of skin from mice that developed allergic dermatitis resembling human atopic dermatitis[17]. Administration of anti-IL-31 or anti-IL-31RA neutralizing Ab resulted in attenuation of scratching behavior, but not the severity of skin inflammation, in that mouse model[18,19] or in patients with atopic dermatitis[20]. On the other hand, the role of IL-31 in the development of contact dermatitis/contact hypersensitivity (CHS) is not well understood. CHS is a T-cell-mediated cutaneous allergic response[21]. Several studies using type-2-cytokine-deficient mice showed that type-2 cytokines are important for the development of CHS (reviewed in[22]), suggesting that IL-31 may be involved in induction of CHS. Il31ra−/− mice showed enhanced type-2 immune responses due to hyperresponsiveness to OSM by increased formation of OSM receptors (the complex of gp130 and OSMR) rather than due to failure to form IL-31 receptors (the complex of IL-31RA and OSMR)[13]. Accordingly, we deemed that murine strain to be unsuitable for examining the role of IL-31 in CHS, and we instead used IL-31-deficient (Il31−/−) mice, which we newly generated.

Results

Generation of Il31−/− mice

Il31ra−/− mice were reported to have not only loss of IL-31 function but also elevated responsiveness to OSM[13], suggesting that it is necessary to elucidate the exact roles of IL-31 in vivo by using Il31−/− mice rather than Il31ra−/− mice. Therefore, we newly generated Il31−/− mice by replacing Il31 genes with a cassette consisting of IRES-EGFP and a neomycin resistance gene, flanked by loxP sequences (Fig. 1a). Il31−/− mice were born at the expected Mendelian ratio, fertile, and did not show any gross phenotypic abnormalities under specific-pathogen-free housing conditions (data not shown). Expression of Il31 mRNA was below the limit of detection by qPCR in the lung and in PMA-ionomycin-stimulated spleen cells of Il31−/− mice (Fig. 1b and data not shown). No apparent abnormalities were found in the proportions of immune cells in the thymus, LNs, spleen and/or bone marrow between wild-type and Il31−/− mice (Fig. 1c, and data not shown).
Figure 1

Generation of Il31−/− mice. (a) IL-31 gene targeting strategy. The region containing a part of exon 2 and exon 3 of Il31 was replaced with a cassette consisting of IRES-EGFP and a neomycin resistance gene (Neor), flanked by loxP sequences. (b) Expression of Il31 mRNA in lung tissue from wild-type (n = 8) and Il31−/− (n = 8) mice by qPCR. The data show the mean + SEM. (c) Leukocyte profiles in the spleen from wild-type and Il31−/− mice (n = 3). The percentages of CD19+ CD3− and CD19− CD3+ cells and of Gr1+ Siglec F− and Gr1- Siglec F+ cells in 7-AAD-negative spleen cells, and the percentages of CD8+ CD4− and CD8− CD4+ cells in 7-AAD-negative CD3+ spleen cells are shown. Representative flow cytometry data are shown.

Generation of Il31−/− mice. (a) IL-31 gene targeting strategy. The region containing a part of exon 2 and exon 3 of Il31 was replaced with a cassette consisting of IRES-EGFP and a neomycin resistance gene (Neor), flanked by loxP sequences. (b) Expression of Il31 mRNA in lung tissue from wild-type (n = 8) and Il31−/− (n = 8) mice by qPCR. The data show the mean + SEM. (c) Leukocyte profiles in the spleen from wild-type and Il31−/− mice (n = 3). The percentages of CD19+ CD3− and CD19CD3+ cells and of Gr1+ Siglec F− and Gr1- Siglec F+ cells in 7-AAD-negative spleen cells, and the percentages of CD8+ CD4− and CD8− CD4+ cells in 7-AAD-negative CD3+ spleen cells are shown. Representative flow cytometry data are shown.

IL-31 is not essential for skin DC function or hapten-specific LN cell response in the sensitization phase of CHS

Treatment of mice that developed atopic dermatitis-like skin inflammation with anti-IL-31 or anti-IL-31RA neutralizing Ab resulted in attenuation of scratching behavior, but not the severity of skin inflammation[18,19]. On the other hand, the role of IL-31 in the development of CHS is not well understood. After epicutaneous exposure to haptens, skin DCs capture the haptens and migrate from the skin into draining LNs, followed by antigen presentation to naïve T cells to induce hapten-specific T cells[21]. To elucidate the role of IL-31 in skin DC migration and maturation, wild-type and Il31−/− mice were treated epicutaneously with FITC. Twenty-four hours later, the proportion of FITC-positive cells among MHC class IIhi CD11c+ cells in draining LNs and their expression of co-stimulatory molecules were determined by flow cytometry. The proportions of FITC-positive cells were comparable between the wild-type and Il31−/− mice (Fig. 2a). Such co-stimulatory molecules as CD86, CD40 and OX40L on the FITC-positive cells were also similarly expressed in the Il31−/− and wild-type mice (Fig. 2b).
Figure 2

Normal skin DC function in Il31−/− mice. (a) The proportion of FITC-positive cells among 7-AAD-negative MHC class IIhi CD11c+ cells in draining LNs from wild-type (n = 4) and Il31−/− (n = 4) mice 24 hours after sensitization with FITC or vehicle alone was determined by flow cytometry. Representative flow cytometric data are shown. Shaded areas = LNs obtained from the vehicle-treated left ear (lower number [%]), and solid lines = LNs obtained from the FITC-treated right ear (upper number [%]). The data show the mean + SEM. (b) The expression levels of CD86, CD40 and OX40L on 7-AAD-negative MHC class IIhi CD11c+ FITC-positive cells in draining LNs from wild-type and Il31−/− mice 24 hours after sensitization with FITC or vehicle alone were determined by flow cytometry. Representative flow cytometric data are shown for wild-type (n = 6) and Il31−/− (n = 4) mice. Shaded areas = isotype-matched control Ig staining, and solid lines = specific mAb staining.

Normal skin DC function in Il31−/− mice. (a) The proportion of FITC-positive cells among 7-AAD-negative MHC class IIhi CD11c+ cells in draining LNs from wild-type (n = 4) and Il31−/− (n = 4) mice 24 hours after sensitization with FITC or vehicle alone was determined by flow cytometry. Representative flow cytometric data are shown. Shaded areas = LNs obtained from the vehicle-treated left ear (lower number [%]), and solid lines = LNs obtained from the FITC-treated right ear (upper number [%]). The data show the mean + SEM. (b) The expression levels of CD86, CD40 and OX40L on 7-AAD-negative MHC class IIhi CD11c+ FITC-positive cells in draining LNs from wild-type and Il31−/− mice 24 hours after sensitization with FITC or vehicle alone were determined by flow cytometry. Representative flow cytometric data are shown for wild-type (n = 6) and Il31−/− (n = 4) mice. Shaded areas = isotype-matched control Ig staining, and solid lines = specific mAb staining. We next elucidated whether the lack of IL-31 influenced hapten-specific T-cell induction in the sensitization phase of CHS. After epicutaneous sensitization of Il31−/− and wild-type mice with FITC, draining LN cells were harvested and cultured in the presence and absence of FITC. After 48 and 72 hours of culture, the levels of IFN-γ, IL-4 and IL-17 in the culture supernatants were comparable in the two mouse strains (Fig. 3). Therefore, these observations suggest that, for the sensitization phase of CHS, IL-31 is not essential for such skin DC functions as migration, maturation and hapten-specific T-cell induction.
Figure 3

Normal hapten-specific LN cell responses in Il31−/− mice. (a) LN cells from FITC-sensitized wild-type (n = 5) and Il31−/− (n = 5) mice were cultured in the presence and absence of 40 μg/ml FITC for 48 and 72 hours. The levels of IFN-γ, IL-4 and IL-17 in the culture supernatants were determined by ELISA. The data show the mean + SEM.

Normal hapten-specific LN cell responses in Il31−/− mice. (a) LN cells from FITC-sensitized wild-type (n = 5) and Il31−/− (n = 5) mice were cultured in the presence and absence of 40 μg/ml FITC for 48 and 72 hours. The levels of IFN-γ, IL-4 and IL-17 in the culture supernatants were determined by ELISA. The data show the mean + SEM.

IL-31 is involved in pruritus, but not inflammation, during CHS

We next investigated whether IL-31 is involved in the pathogenesis of FITC-induced CHS. The degree of skin inflammation was assessed by measuring the thickness of the ear skin after challenge with FITC. The ear thickness was comparable between wild-type and Il31−/− mice at the indicated time points after the initial epicutaneous application of FITC (Fig. 4a). The degree of skin inflammation assessed by histological analysis was also similar between the wild-type and Il31−/− mice at 24 hours after challenge with FITC or vehicle (Fig. 4b). We also used ELISA to examine the levels of FITC-specific IgG subsets and total IgE in sera from naïve and FITC-treated mice. After FITC challenge, the levels of FITC-specific IgG1, IgG2b and IgG2c and total IgE in sera from Il31−/− mice increased similarly to those from wild-type mice (Fig. 4c). On the other hand, the scratching frequency and duration were significantly decreased in Il31−/− mice compared with wild-type mice at 24 hours after FITC challenge (Fig. 5). Similar phenotypes were also observed for Il31−/− mice during DNFB-induced CHS. Although the ear thickness was slightly, but not significantly, increased in Il31−/− mice compared with wild-type mice at the indicated time points after the initial epicutaneous application of DNFB (Fig. 6a), the scratching frequency and duration were significantly decreased in Il31−/− mice compared with wild-type mice at 24 hours after DNFB challenge (Fig. 6b). GFP+ cells were hardly detected in LNs from Il31gfp/+ mice during DNFB-induced CHS (data not shown). We found that a part of F4/80+ and CD11c+ cells, but not CD3+ cells, Gr1+ cells and tryptase+ cells (data not shown), were producers of IL-31 in skin from wild-type mice, but not Il31−/− mice, at 24 h after DNFB challenge (Fig. 7). The signals in keratinocytes from wild-type mice were due to non-specific binding of the anti-IL-31 Ab, since they were detected even in Il31−/− mice (Fig. 7). These observations suggest that IL-31 is important for induction of pruritus, but not inflammation, in CHS induced by FITC and DNFB.
Figure 4

IL-31 is not essential for skin inflammation during FITC-induced CHS. (a) Wild-type (n = 47) and Il31−/− (n = 41) mice were epicutaneously sensitized and challenged with FITC. The ear skin thickness of the mice was measured at the indicated time points after challenge with FITC or vehicle alone. The data show the mean + SEM. (b) Sections of ear skin from wild-type and Il31−/− mice at 24 hours after challenge with FITC or vehicle alone were stained with hematoxylin and eosin. Representative data are shown. Scale bar = 50 μm. (c) Ninety-six hours after challenge with FITC, sera were collected from wild-type (n = 5 [naïve], and n = 21 [FITC]) and Il31−/− (n = 5 [naïve], and n = 15 [FITC]) mice. The levels of FITC-specific IgG1, IgG2a and IgG2c and total IgE in the sera were determined by ELISA. The data show the mean + SEM.

Figure 5

IL-31 is important for pruritus during FITC-induced CHS. (a) Scratching behavior (number of times and duration) in wild-type (n = 12–14) and Il31−/− (n = 12–15) mice was assessed at 24 and 48 hours after challenge with FITC or vehicle alone. The data show the mean + SEM. *p < 0.05 and **p < 0.01.

Figure 6

IL-31 is important for pruritus, but not skin inflammation, during DNFB-induced CHS. (a) Wild-type (n = 12) and Il31−/− (n = 12) mice were epicutaneously sensitized and challenged with DNFB. The ear skin thickness of the mice was measured at the indicated time points after challenge with DNFB or vehicle alone. The data show the mean + SEM. (b) Scratching behavior (number of times and duration) in wild-type (WT; n = 8–13) and Il31−/− (n = 8–12) mice was assessed at 24 and 48 hours after challenge with DNFB or vehicle alone. The data show the mean + SEM. *p < 0.05 and **p < 0.01.

Figure 7

IL-31 is produced by macrophages and dermal DCs in the skin during DNFB-induced CHS. Wild-type and Il31−/− mice were epicutaneously sensitized and challenged with DNFB. 24 h after the epicutaneous challenge with DNFB or vehicle alone, the ear skin was collected. IL-31 expression in sections of the ear skin was detected by immunohistochemistry. Arrowhead(s) = representative IL-31+ F4/80+ cells or IL-31+ CD11c+ cells.

IL-31 is not essential for skin inflammation during FITC-induced CHS. (a) Wild-type (n = 47) and Il31−/− (n = 41) mice were epicutaneously sensitized and challenged with FITC. The ear skin thickness of the mice was measured at the indicated time points after challenge with FITC or vehicle alone. The data show the mean + SEM. (b) Sections of ear skin from wild-type and Il31−/− mice at 24 hours after challenge with FITC or vehicle alone were stained with hematoxylin and eosin. Representative data are shown. Scale bar = 50 μm. (c) Ninety-six hours after challenge with FITC, sera were collected from wild-type (n = 5 [naïve], and n = 21 [FITC]) and Il31−/− (n = 5 [naïve], and n = 15 [FITC]) mice. The levels of FITC-specific IgG1, IgG2a and IgG2c and total IgE in the sera were determined by ELISA. The data show the mean + SEM. IL-31 is important for pruritus during FITC-induced CHS. (a) Scratching behavior (number of times and duration) in wild-type (n = 12–14) and Il31−/− (n = 12–15) mice was assessed at 24 and 48 hours after challenge with FITC or vehicle alone. The data show the mean + SEM. *p < 0.05 and **p < 0.01. IL-31 is important for pruritus, but not skin inflammation, during DNFB-induced CHS. (a) Wild-type (n = 12) and Il31−/− (n = 12) mice were epicutaneously sensitized and challenged with DNFB. The ear skin thickness of the mice was measured at the indicated time points after challenge with DNFB or vehicle alone. The data show the mean + SEM. (b) Scratching behavior (number of times and duration) in wild-type (WT; n = 8–13) and Il31−/− (n = 8–12) mice was assessed at 24 and 48 hours after challenge with DNFB or vehicle alone. The data show the mean + SEM. *p < 0.05 and **p < 0.01. IL-31 is produced by macrophages and dermal DCs in the skin during DNFB-induced CHS. Wild-type and Il31−/− mice were epicutaneously sensitized and challenged with DNFB. 24 h after the epicutaneous challenge with DNFB or vehicle alone, the ear skin was collected. IL-31 expression in sections of the ear skin was detected by immunohistochemistry. Arrowhead(s) = representative IL-31+ F4/80+ cells or IL-31+ CD11c+ cells.

Discussion

IL-31 is preferentially produced by Th2 cells in Th subsets, and excessive IL-31 production in IL-31 Tg mice resulted in development of dermatitis due to enhancement of type–2 immune responses[1]. By contrast, Il31ra−/− mice showed enhanced type–2 immune responses during nematode infection[23], suggesting that IL-31R signaling has a suppressive role in type-2 immune responses. Regarding the apparent discrepancies in phenotype between IL-31 Tg mice[1] and Il31ra−/− mice[23], the latter were reported to be hyperresponsive to OSM due to increased formation of OSM receptors (gp130 and OSMR) caused by the lack of IL-31R (IL-31RA and OSMR), resulting in OSM-mediated suppression of type–2 immune responses[13]. Therefore, to investigate the precise role of IL-31 in vivo, we newly generated Il31−/− mice for the present study. Using those mice, we demonstrated for the first time that IL-31 is important for induction of pruritus, but not inflammation, in CHS induced by FITC and DNFB. IL-31 is considered to be involved in the pathogenesis of type–2 cytokine-associated allergic disorders such as rhinitis, asthma and dermatitis[5]. In support of that notion, the levels of IL-31 were increased in patients with allergic rhinitis[11], asthma[12] and atopic dermatitis[14,15]. DNFB- and/or FITC-induced CHS was attenuated in Il4−/− mice[24,25] and/or stat6−/− mice[26], suggesting that type-2 cytokines are important for induction of DNFB- and/or FITC-induced CHS. In addition, the levels of IL-31 were also elevated in patients with contact dermatitis[16]. These observations suggest that IL-31 may be involved in induction of type-2-cytokine-associated CHS. However, we demonstrated that Il31−/− mice showed normal migration and maturation of skin DCs and induction of hapten-specific T cells in the sensitization phase of FITC-induced CHS, and normal induction of local inflammation in the elicitation phase of FITC- and DNFB-induced CHS, indicating that IL-31 is not essential for induction of skin inflammation during FITC- or DNFB-induced CHS. As a unique function of IL-31, it is known to be involved in itching via signal activation of IL-31 receptors on sensory nerve cells[5,27]. Indeed, IL-31 Tg mice show severe scratching behavior accompanied by exfoliation of epidermis[1]. Administration of anti-IL-31 or anti-IL-31RA neutralizing Ab resulted in attenuation of scratching behavior, but not the severity of skin inflammation, in mice that developed atopic dermatitis-like skin inflammation[18,19]. Consistent with this, we showed that Il31−/− mice had reduced scratching frequency and duration in FITC- and/or DNFB-induced CHS, indicating that IL-31 is responsible for pruritus in the setting. However, the underlying mechanism of this remains unclear and should be further investigated in future studies. In summary, we demonstrated here that IL-31 is involved in pruritus reactions without affecting induction of local skin inflammation in CHS.

Methods

Mice

C57BL/6 N wild-type mice were obtained from Japan SLC, Inc. (Hamamatsu, Japan). Il31−/− mice on the C57BL/6 N background were generated as follows. The Il31 gene was disrupted by replacement of the region from a part of exon 2 to a part of the intron behind exon 3 with a cassette consisting of IRES-EGFP and a neomycin resistance gene, flanked by loxP sequences (Fig. 1a). Homologous regions were amplified by PCR using the following primers: 5′-CAACCTATTCCTAGTTCCCTCACC-3′ and 5′-AAAGCAGCACCAGGGTAGGCTTCG-3′ to generate a 6-kb fragment, and 5′- TGAATGAGGGGAACAGAAAATTACC-3′ and 5′-TGATGAATAATGATATTCCTTACC-3′ to generate a 2-kb fragment. The targeting vector was electroporated into C57BL/6 N ES cells (EGR-101, kindly provided by Dr. Masaru Okabe, Osaka University). Male chimeric mice were obtained from three distinct targeted clones and mated with C57BL/6 N female mice. Genotyping of Il31−/− mice was performed by PCR using the following primers: common 1 (5′-GACAACCCTTTATATATTGCCTGG-3′), WT 1 (5′-GCTTCCATAGCTGGCTTTATATCG-3′) and IL-31 KO (5′-CGACACCGGCCTTATTCCAAGCGG-3′). The common 1 and WT 1 primers were used for detection of wild-type alleles (~550 bp), and the common and IL-31 KO primers were used for detection of mutant alleles (~390 bp). For generation of Il31 mice, a plasmid carrying Cre cDNA (pCAG-Cre, kindly provided by Dr. Jun-ichi Miyazaki, Osaka University) was injected into fertilized eggs from Il31−/− mice to deplete the neomycin resistance gene, and it was flanked by loxP sequences. The eggs were then transferred into pseudopregnant female mice. Genotyping of Il31 mice was performed by PCR using the following primers: common 2 (5′-TGGGAAGATACATGAAACCAATCC-3′), WT 2 (5′-CACTGGCTGCTCTTCCAGAGGACC-3′) and Neor (5′-GACGTGCTACTTCCATTTGTCACG-3′). The common and WT primers were used for detection of wild-type alleles (~493 bp), and the common and Neor primers were used for detection of mutant alleles (no band). All mice were housed in a specific-pathogen-free environment at The Institute of Medical Science, The University of Tokyo. The animal protocol for experiments was approved by the Institutional Review Board of the Institute (A11-28 and A14-10), and all experiments were conducted according to the ethical and safety guidelines of the Institute.

Quantitative PCR

Total RNA was prepared from lungs using Sepasol (Nacalai Tesque, Inc.) and treated with DNase (TURBO DNA-free-kit; Thermo Fisher Scientific Inc., MA). cDNA was synthesized from the isolated RNA by RT-PCR (PrimeScript RT Reagent kit; TAKARA BIO Inc., Shiga, Japan). Quantitative real-time PCR was performed with SYBER Premix Ex Taq (TAKARA BIO Inc.) or SYBER Premix DimerEraser (TAKARA BIO Inc.) using a CFX384TM Touch Real-time PCR Detection System (BioRad Laboratories, Inc., Hercules, CA). Relative gene expression was determined against HPRT gene expression. The following PCR primers were designed: forward primer 5′-ATACAGCTGCCGTGTTTCAG-3′ and reverse primer 5′-AGCCATCTTATCACCCAAGAA-3′ for Il31 mRNA; and forward primer 5′-GGCCAGACTTTGTTGGATTTG-3′ and reverse primer 5′-CGCTCATCTTAGGCTTTGTATTTG-3′ for Hprt mRNA.

Flow cytometry

Spleen cells were incubated with anti-mouse CD16/CD32 mAb (2.4G2; BD Biosciences, San Jose, CA) in FACS buffer (HBSS containing 2% FCS) for FcR blocking for 15 min on ice, and then incubated with BV421-conjugated anti-mouse CD3 mAb (145-2C11; Biolegend, San Diego, CA), APC-conjugated anti-mouse CD8 mAb (53-6.7; Biolegend), PE-conjugated anti-mouse CD4 (GK1.5 Biolegend) or Siglec F (E50-2440; BD Biosciences) mAb, PE-Cy7-conjugated anti-mouse CD19 mAb (6D5; Biolegend) or Gr1 (RB6-8C5; Affymetrix eBioscience, San Diego, CA) mAb for 20 min on ice. The expression profile of each cell surface marker on 7-aminoactinomycin D (7-AAD; Sigma-Aldrich Co. LLC, St. Louis, MO) -negative cells was analyzed on a MACSQuant Analyser (Miltenyi Biotec, Bergisch Gladbach, Germany) with MACSQuantify Software (Miltenyi Biotec) and FlowJo software (Tree Star Inc., Ashland, OR).

Skin DC migration

Skin DC migration was determined as described elsewhere[28]. In brief, mice were epicutaneously treated with 40 µl of 0.5% (w/v) FITC isomer I (Sigma-Aldrich Co. LLC) in a 1:1 mixture of acetone (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and dibutyl phthalate (Sigma-Aldrich Co. LLC) (20 µl to each surface of the left ear) and the vehicle alone (20 µl to each surface of the right ear). Twenty-four hours later, submaxillary lymph nodes (LNs) were separately collected from both the FITC-treated left and vehicle-treated right ears. After incubation with anti-mouse CD16/CD32 mAb (2.4G2, BD Biosciences) for 15 minutes on ice, LN cells were stained with PE-conjugated anti-mouse CD11c mAb (HL3, BD Biosciences) and APC-conjugated anti-mouse MHC Class II (I-A/I-E) mAb (M5/114.15.2, Affymetrix eBioscience) for 20 minutes on ice. The percentage of FITC-positive cells among 7-AAD-negative MHC Class IIhi CD11c+ cells was determined using a FACS Verse (BD Biosciences), and data analyses were performed using FlowJo software (Tree Star Inc.).

Skin DC maturation

A shaved area on the back and both surfaces of both ears of mice were painted with 150 µl and 20 µl of 0.5% FITC isomer I, respectively. Twenty-four hours later, inguinal, axillary and submaxillary LNs were harvested and pooled. LN single-cell suspensions were prepared and incubated with anti-mouse CD16/CD32 mAb for 15 minutes on ice. The cells were then stained with APC-conjugated MHC-class II mAb, PE-Cy7-conjugated anti-mouse CD11c mAb, and PE-conjugated mAb for CD86 (GL-1, Biolegend), CD40 (3/23, Biolegend) or OX40L (RM134L, Biolegend) for 20 minutes on ice. The expression levels of CD86, CD40 and OX40L on 7-AAD-negative MHC Class IIhi CD11c+ FITC+ cells were determined using a FACS Verse (BD Biosciences), and data analyses were performed using FlowJo software (Tree Star Inc.).

Induction of contact hypersensitivity (CHS)

CHS was induced with FITC and DNFB as described elsewhere[28,29]. Briefly, 2 days after shaving the back hair with electrical clippers, the back skin was treated with 150 µl of 1.0% FITC isomer I in a 1:1 mixture of acetone and dibutyl phthalate or 25 µl of 0.5% DNFB (SIGMA) in a 4:1 mixture of acetone and olive oil. Five days later, the respective mice were challenged with 40 µl of 0.5% FITC isomer I or 0.2% DNFB (each surface of the left ear) and 40 µl of the vehicle alone (each surface of the right ear). The ear thickness was measured before and after FITC challenge using dial thickness gauges (Ozaki MFG. Co., Ltd., Tokyo, Japan).

Measurement of levels of serum immunoglobulins

Sera were collected from mice 4 days after FITC challenge during FITC-induced CHS. The levels of FITC-specific Igs in the sera were determined by ELISA as described elsewhere[29]. In brief, 96-well flat-bottom plates (Thermo Fisher Scientific Inc.) were coated with 20 µg/ml FITC-conjugated OVA at 4 °C overnight. After the wells were blocked with PBS containing 1% FBS, optimally diluted serum samples (IgG1 = 1/100; IgG2b = 1/100; IgG2c = 1/10) were placed in the wells, and the plates were incubated at room temperature for 2 hours. After washing, HRP-conjugated anti-mouse IgG1, IgG2b or IgG2c mAb (Bethyl Laboratories, Inc., TX) was added, followed by incubation at room temperature for 1 hour. For enzymatic reaction, TMB substrate (Nacalai Tesque Inc.) was used as a substrate. The reaction was stopped by addition of 0.2 M H2SO4, and then the absorbance (450 nm) was measured using a VersaMax (Molecular Devices, LLC, Sunnyvale, CA). Data show the absorbance value at 450 nm. The levels of total IgE in sera were determined using an ELISA kit (Bethyl Laboratories, Inc.) in accordance with the manufacturer’s instructions.

FITC-specific LN cell responses

FITC-specific LN cell responses were determined as described elsewhere[28,29]. Briefly, mice were epicutaneously treated with 1.0% FITC isomer I in a 1:1 mixture of acetone and dibutyl phthalate on both the left and right ears (20 μl on one surface of each ear). Six days later, submaxillary LNs were collected. The LN cells were cultured in the presence and absence of 40 μg/ml FITC at 37 °C for 72 hours. The levels of cytokines in each culture supernatant were determined with mouse IFN-γ, IL-4 and IL-17A ELISA kits obtained from Biolegend (San Diego, CA) or Peprotech (Rocky Hill, NJ).

Assessment of scratching behaviour

SCLABA-Real (NOVELTEC) was used to assess scratching behavior (frequency and duration) at 24 and 48 hours after challenge with FITC or DNFB during FITC- or DNFB-induced CHS.

Histology

Twenty-four hours after FITC or vehicle challenge, the ear skins were harvested, fixed in Carnoy’s fluid and embedded in paraffin. Sections were prepared and stained with hematoxylin-eosin.

Immunohistochemistry

Twenty-four hours after epicutaneous challenge with DNFB as described above, the ear skin was frozen in OCT compound (Sakura Finetek, Tokyo, Japan). Sections (4.5-μm thick) were prepared using a cryostat (Leica) and dried on aminosilane-coated slide glasses (Matsunami Glass, Osaka, Japan). The sections were fixed in 4% paraformaldehyde at room temperature for 10 min and incubated with Blocking One Histo (Nacalai Tesque, Inc.) and Avidin/Biotin Blocking Kit (Vector Laboratories, CA) at room temperature for 10 min. They were then incubated with primary Abs, rabbit anti-mouse CD3 Ab (ab5690; Abcam plc., Tokyo, Japan), hamster anti-mouse CD11c Ab (ab33484; Abcam plc.), rat anti-mouse F4/80 (MCA497GA; Bio-Rad), biotin-conjugated goat anti-mouse IL-31 Ab (BAF3028; R&D Systems), rat anti-mouse Ly-6G/-6C Ab (ab2557; Abcam plc.) or rabbit anti-mouse tryptase Ab (ab134932; Abcam plc.), at 4 °C overnight. After washing, the sections were incubated with secondary Abs/reagent, Alexa fluor® 594-conjugated donkey anti-rabbit Ab (ab150064; Abcam plc.), Alexa fluor® 594-conjugated donkey anti-rat Ab (ab150156; Abcam plc.), Alexa fluor® 594-conjugated goat anti-hamster Ab (A21113: Thermo Fisher Scientific), or Alexa fluor® 488-conjugated streptavidin (S11223: Thermo Fisher Scientific), at 4 °C for 60 min. Nuclei were stained with DAPI (R37606; Thermo Fisher Scientific). Images were acquired using a fluorescent microscope (BZX-700, KEYENCE, Tokyo, Japan) and analyzed with a software (BZ-analysis application, KEYENCE).

Statistics

A two-tailed Mann-Whitney U test was performed for statistical significance using Graphpad Prism software (Graphpad Prism). P values of less than 0.05 were considered statistically significant.
  29 in total

1.  Correlation of IL-31 serum levels with severity of atopic dermatitis.

Authors:  Ulrike Raap; Katja Wichmann; Manuela Bruder; Sonja Ständer; Bettina Wedi; Alexander Kapp; Thomas Werfel
Journal:  J Allergy Clin Immunol       Date:  2008-08       Impact factor: 10.793

2.  Inhibition of allergic contact dermatitis to DNCB but not to oxazolone in interleukin-4-deficient mice.

Authors:  C Traidl; F Jugert; T Krieg; H Merk; N Hunzelmann
Journal:  J Invest Dermatol       Date:  1999-04       Impact factor: 8.551

3.  Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis.

Authors:  Akiko Takaoka; Iwao Arai; Masanori Sugimoto; Akie Yamaguchi; Makoto Tanaka; Shiro Nakaike
Journal:  Eur J Pharmacol       Date:  2005-06-01       Impact factor: 4.432

4.  Ultraviolet B radiation and reactive oxygen species modulate interleukin-31 expression in T lymphocytes, monocytes and dendritic cells.

Authors:  C Cornelissen; R Brans; K Czaja; C Skazik; Y Marquardt; G Zwadlo-Klarwasser; A Kim; D R Bickers; J Lüscher-Firzlaff; B Lüscher; J M Baron
Journal:  Br J Dermatol       Date:  2011-10-17       Impact factor: 9.302

5.  Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis.

Authors:  Mark M Neis; Bettina Peters; Alexandra Dreuw; Joerg Wenzel; Thomas Bieber; Cornelia Mauch; Thomas Krieg; Sven Stanzel; Peter C Heinrich; Hans F Merk; Andreas Bosio; Jens M Baron; Heike M Hermanns
Journal:  J Allergy Clin Immunol       Date:  2006-09-01       Impact factor: 10.793

Review 6.  Th17 and allergy.

Authors:  Keisuke Oboki; Tatsukuni Ohno; Hirohisa Saito; Susumu Nakae
Journal:  Allergol Int       Date:  2008-06       Impact factor: 5.836

7.  Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice.

Authors:  Stacey R Dillon; Cindy Sprecher; Angela Hammond; Janine Bilsborough; Maryland Rosenfeld-Franklin; Scott R Presnell; Harald S Haugen; Mark Maurer; Brandon Harder; Janet Johnston; Susan Bort; Sherri Mudri; Joseph L Kuijper; Tom Bukowski; Pamela Shea; Dennis L Dong; Maria Dasovich; Francis J Grant; Luann Lockwood; Steven D Levin; Cosette LeCiel; Kim Waggie; Heather Day; Stavros Topouzis; Janet Kramer; Rolf Kuestner; Zhi Chen; Don Foster; Julia Parrish-Novak; Jane A Gross
Journal:  Nat Immunol       Date:  2004-06-06       Impact factor: 25.606

8.  Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders.

Authors:  Takefumi Ishii; Jiapeng Wang; Wei Zhang; John Mascarenhas; Ronald Hoffman; Ying Dai; Nathaniel Wisch; Mingjiang Xu
Journal:  Blood       Date:  2009-02-04       Impact factor: 22.113

9.  Dendritic cells activated by IFN-γ/STAT1 express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment.

Authors:  Jutta Horejs-Hoeck; Harald Schwarz; Sebastian Lamprecht; Elisabeth Maier; Stefan Hainzl; Maria Schmittner; Gernot Posselt; Angelika Stoecklinger; Thomas Hawranek; Albert Duschl
Journal:  J Immunol       Date:  2012-04-25       Impact factor: 5.422

10.  The release of IL-31 and IL-13 after nasal allergen challenge and their relation to nasal symptoms.

Authors:  Ralf Baumann; Matthaeus Rabaszowski; Igor Stenin; Maria Gaertner-Akerboom; Kathrin Scheckenbach; Jens Wiltfang; Joerg Schipper; Martin Wagenmann
Journal:  Clin Transl Allergy       Date:  2012-08-01       Impact factor: 5.871

View more
  23 in total

Review 1.  Interleukin 30 to Interleukin 40.

Authors:  Jovani Catalan-Dibene; Laura L McIntyre; Albert Zlotnik
Journal:  J Interferon Cytokine Res       Date:  2018-10       Impact factor: 2.607

Review 2.  Choreographing Immunity in the Skin Epithelial Barrier.

Authors:  Tetsuro Kobayashi; Shruti Naik; Keisuke Nagao
Journal:  Immunity       Date:  2019-03-19       Impact factor: 31.745

3.  Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.

Authors:  Saadet Inan; Alvaro Torres-Huerta; Liselotte E Jensen; Nae J Dun; Alan Cowan
Journal:  Eur J Pharmacol       Date:  2019-09-27       Impact factor: 4.432

4.  Inhibition of natriuretic peptide receptor 1 reduces itch in mice.

Authors:  Hans Jürgen Solinski; Patricia Dranchak; Erin Oliphant; Xinglong Gu; Thomas W Earnest; John Braisted; James Inglese; Mark A Hoon
Journal:  Sci Transl Med       Date:  2019-07-10       Impact factor: 17.956

5.  Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled Receptors Drives Non-histaminergic Itch.

Authors:  James Meixiong; Michael Anderson; Nathachit Limjunyawong; Mark F Sabbagh; Eric Hu; Madison R Mack; Landon K Oetjen; Fang Wang; Brian S Kim; Xinzhong Dong
Journal:  Immunity       Date:  2019-04-23       Impact factor: 31.745

Review 6.  The Neuroimmune Axis in Skin Sensation, Inflammation, and Immunity.

Authors:  Anna M Trier; Madison R Mack; Brian S Kim
Journal:  J Immunol       Date:  2019-05-15       Impact factor: 5.422

Review 7.  The New Era of Biologics in Atopic Dermatitis: A Review.

Authors:  Simon Schneider; Linda Li; Alexander Zink
Journal:  Dermatol Pract Concept       Date:  2021-10-01

Review 8.  IL-31: State of the Art for an Inflammation-Oriented Interleukin.

Authors:  Francesco Borgia; Paolo Custurone; Federica Li Pomi; Raffaele Cordiano; Clara Alessandrello; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

9.  Role of Mast Cells in the Pathogenesis of Pruritus in Mastocytosis.

Authors:  Dominika Kwiatkowska; Adam Reich
Journal:  Acta Derm Venereol       Date:  2021-10-31       Impact factor: 3.875

10.  Single-cell transcriptomic analysis of allergen-specific T cells in allergy and asthma.

Authors:  Grégory Seumois; Ciro Ramírez-Suástegui; Benjamin J Schmiedel; Shu Liang; Bjoern Peters; Alessandro Sette; Pandurangan Vijayanand
Journal:  Sci Immunol       Date:  2020-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.